Home > Oncology > ESMO 2022 > High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer

High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer

Presented By
Dr Miriam Chalabi, Netherlands Cancer Institute, the Netherlands
Conference
ESMO 2022
Trial
Phase 2, NICHE-2
Treatment with neoadjuvant immunotherapy (nivolumab/ipilimumab) for 4 weeks achieved a major pathological response in 95% of patients with stage III mismatch repair-deficient (dMMR) colon cancer, the first results of NICHE-2 trial show. Approximately 10–15% of non-metastatic colon cancers are dMMR, of which about one third are associated with Lynch syndrome [1]. Patients with stage III dMMR tumours have recurrence rates of 20–40%, despite standard-of-care chemotherapy [2]. In addition, high-risk disease (T4 or N2) is associated with poor survival. Neoadjuvant chemotherapy in patients with dMMR colon cancer leads to a pathological response of 5–7% [3]. On the other hand, neoadjuvant immunotherapy leads to high pathological responses in many tumour types, e.g. melanoma, that are associated with excellent survival outcomes [4]. Previously, results from the proof-of-concept NICHE-1 trial (n=32) showed that immune checkpoint inhibition is highly effectiv...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on